Monitor the vote results for the equity incentive plan increase, as approval could lead to share dilution. The other proposals are standard governance items unlikely to impact operations.
ATRA drugs
ATRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $4.99entry
- T+1 · 7mo ago −5.21%α −4.73% · $4.73
- T+5 · 7mo ago −2.20%α −2.60% · $4.88
- T+20 · 6mo ago +92.59%α +87.63% · $9.61
- T+60 · 4mo ago +62.83%α +58.05% · $8.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two directors, approving executive compensation, increasing shares in its equity incentive plan by 400,000, and ratifying Deloitte & Touche as its auditor. The filing is a routine proxy statement from management.
Key Financial Metrics
Key Facts
- Annual meeting to vote on director elections, executive compensation, equity plan increase, and auditor ratification
- Management is soliciting votes for all proposals
- No activist involvement or contested board seats
- Routine annual corporate governance matters
Financial Impact
400,000 additional shares authorized in equity incentive plan
Risk Factors
- Potential share dilution from the equity plan increase
- Shareholder opposition to executive compensation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177280 |
| Document: 0001193125-26-177280-index-headers.html | 0001193125-26-177280 |
| Document: 0001193125-26-177280-index.html | 0001193125-26-177280 |
| Document: 0001193125-26-177280.txt | 0001193125-26-177280 |
Track record
11 reports on ATRA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
- Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
- Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
- Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
- Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers